We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/11/2019 12:55 | Morning from the States Whats driving this? | ih_198062 | |
04/11/2019 12:26 | Looking good | nw99 | |
04/11/2019 11:50 | Tried twice to buy | john09 | |
04/11/2019 11:23 | Just love those stream of buys this am | ayl30 | |
04/11/2019 10:49 | I’ve an order in. Not filled yet | john09 | |
04/11/2019 10:00 | 340 being paid now. | mfhmfh | |
02/11/2019 16:04 | 😂👌 yep I spotted that a mile off | john09 | |
29/10/2019 21:03 | For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch. Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. - "When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million. That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time." (16:36 onwards) | sunningdale1 | |
24/10/2019 13:42 | Below is link to a letter sent by Cel-Sci's CEO to all of their shareholders today. Have to say, it seems to be a highly unusual approach. Hope the trial is a success, otherwise I'm not sure that letter is going to age well. | bermudashorts | |
23/10/2019 16:21 | Big trades Lets keep an eye on the RNS reporting tomorrow | ih_198062 | |
23/10/2019 09:22 | 111,250 shares bought this morning followed by 100,000 shares bought straight afterwards. | mfhmfh | |
22/10/2019 08:15 | And again today | ayl30 | |
18/10/2019 13:21 | Streams of buys coming in today | mfhmfh | |
11/10/2019 14:09 | nice chart | onjohn | |
10/10/2019 12:56 | lol - shameless plug there sunningdale. Open Orphan worth watching but have a way to go yet IMO. | bermudashorts | |
10/10/2019 12:25 | Great to hear of the SCSW write up - ERGO appear to back on track after the dip in September - strong board changes and positive interim results have helped and an indication of where the company is going For those interested in the Orphan Drug market / pharma stocks - Open Orphan AIM:ORPH is a stock I’d recommend keeping an eye on - CEO Cathal Friel predicts 40% growth a year on recent podcast below with 2 million of his own money invested. hxxps://audioboom.co The company has a four pronged strategy including a European health data collection platform. For measure GSK recently valued an Alzheimers neurologival disorder database for £300m so big money business. CCO Maurice Treacy explains on proactive | sunningdale1 | |
09/10/2019 14:30 | Buys continuing into the afternoon including a 65,000 buy at 305p. What will move the sp? | mfhmfh | |
09/10/2019 09:30 | Stream of buys this am. Good write up in SCSW | ayl30 | |
07/10/2019 11:33 | Very positive. Much expected A lot of focus on Richard Barfield appointment Unfair to subscribers to post much more. | badday | |
07/10/2019 10:02 | badday What's the general gist of their tip? I am assuming it's a positive recommendation? thanks | mirabeau |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions